The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Mendlein John since 2013.
This trader's CIK number is 1238362.
At the time of last reporting, Mendlein John was the Director of Fate Therapeutics Inc. (stock ticker symbol FATE).
Also see all insider trading activities at Fate Therapeutics Inc.
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2023 | FATE | 124,679 | $698,138 | 0 | $0 | 28,461 | $38,991 |
| 2022 | FATE | 0 | $0 | 32,926 | $1,139,069 | 31,562 | $51,446 |
| 2013 | FATE | 16,667 | $100,002 | 0 | $0 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2018 | LIFE | 245,000 | $103,330 | 0 | $0 | 0 | $0 |
| 2017 | LIFE | 40,412 | $108,028 | 0 | $0 | 0 | $0 |
| 2016 | LIFE | 74,000 | $169,337 | 0 | $0 | 0 | $0 |
1. Fate Therapeutics Inc (FATE)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2023-01-19 | FATE | Option Ex | 28,461 | 1.37 | 38,991 |
| 2023-01-13 | FATE | Buy | 36,631 | 5.43 | 198,906 |
| 2023-01-11 | FATE | Buy | 88,048 | 5.67 | 499,232 |
| 2022-06-03 | FATE | Sale | 1,364 | 22.79 | 31,085 |
| 2022-03-10 | FATE | Option Ex | 31,562 | 1.63 | 51,446 |
| 2022-03-10 | FATE | Sale | 31,562 | 35.10 | 1,107,984 |
| 2013-10-04 | FATE | Buy | 16,667 | 6.00 | 100,002 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2018-12-20 | LIFE | Buy | 50,000 | .41 | 20,650 |
| 2018-12-21 | LIFE | Buy | 195,000 | .42 | 82,680 |
| 2017-08-31 | LIFE | Buy | 37,736 | 2.65 | 100,000 |
| 2017-04-24 | LIFE | Buy | 124 | 3.00 | 372 |
| 2017-04-18 | LIFE | Buy | 1,000 | 3.00 | 3,000 |
| 2017-04-20 | LIFE | Buy | 1,552 | 3.00 | 4,656 |
| 2016-12-19 | LIFE | Buy | 69,000 | 2.20 | 151,662 |
| 2016-04-05 | LIFE | Buy | 2,500 | 3.52 | 8,800 |
| 2016-04-05 | LIFE | Buy | 2,500 | 3.55 | 8,875 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Mendlein John (Director of Fate Therapeutics Inc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.